It emerged a seductive idea: Bridging the gap between genetics and pharmacology could allow clinicians to hit cancer cells where it hurts them most. In May 2004, Iressa, known generically as gefitinib, rose from the ashes of poor clinical trials as an example of how this might work. But this early poster child for pharmacogenetics has yet to live up to its hype.
Advertisement
Survey Series
Institutions
For Advertisers
A Target for Iressa
The fall and rise (and fall) of a pharmacogenetics poster child
|
|||||||||
|
|||||||||
|
